Biopolym. Cell. 2011; 27(2):141-146.
http://dx.doi.org/10.7124/bc.00008D
Molecular Biomedicine
The binding properties of some novel ruthenium (III) complexes with human serum transferrin
1Arsene A. L., 2Uivarosi V., 1Mitrea N., 1Dragoi C. M., 1Nicolae A.
  1. Department of Biochemistry of University of Medicine and Pharmacy "Carol Davila", Faculty of Pharmacy
    6th Traian Vuia St., 020956, Bucharest, Romania
  2. Department of Inorganic Chemistry of University of Medicine and Pharmacy "Carol Davila", Faculty of Pharmacy
    6th Traian Vuia St., 020956, Bucharest, Romania

Abstract

Aim. The transferrin cycle gained increased interest in recent years and it holds promise as an attractive system for strategies of drug targeting to tumors. Neoplasic cells exhibit a large demand of iron and therefore express highly transferrin receptors. As a consequence, transferrin conjugates can preferentially interact with cancer cells. This strategy is exploited nowadays for targeting novel anti-cancer drugs. Recent data showed that ruthenium (III) compounds possess antitumor and antimetastatic effects, due to their affinity for crucial biomolecules (like transferrin). Methods. The paper presents the transferrin-binding properties of some novel ruthenium (III) complexes with general formula RuL2(DMSO)mCl3·nH2O ((Ru-nf) L: norfloxacin (nf), m = 1, n = 1; (Ru-cpx) L: ciprofloxacin (cpx), m = 2, n = 2; (Ru-oflo) L: ofloxacin (oflo), m = 1, n = 1; (Ru-levo) L: levofloxacin (Levo), m = 2, n = 8; (Ru-pip) L: pipemidic acid (pip), m = 1, n = 2, DMSO: dimethylsulfoxide). We investigated, in vitro, the interactions of these ligands with human transferrin through spectroscopic techniques, with the ultimate goal of preparing adducts with good selectivity for cancer cells. Results. All studied complexes interact with human serum transferrin; the molar ratio [complex]/[transferrin] strongly influences the binding affinity. Conclusions. The best interaction between the complexes studied and transferrin is achieved for a molar ratio of 8; the best interaction was registered for Ru-pip, followed by Ru-nf.
Keywords: ruthenium (III) complexes, transferrin
Full text: (PDF, in English)

References

[1] Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs Curr. Pharm. Des 1999 5, N 6 P. 443– 451.
[2] Wagner E., Curiel D., Cotten M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis Adv. Drug. Deliver. Rev 1994 14, N 1 P. 113–135.
[3] Sun H., Li H., Sadler P. J. Transferrin as a metal ion mediator Chem. Rev 1999 99, N 9 P. 2817–2842.
[4] Srivastava S. C., Mausner L. F., Clarke M. J. Radioruthenium-labeled compounds for diagnostic tumor imaging Prog. Clin. Biochem. Med 1989 10 P. 111–149.
[5] Clarke M. J., Zhu F., Frasca D. R. Non-platinum chemotherapeutic metallopharmaceuticals Chem. Rev 1999 99, N 9 P. 2511–2534.
[6] Mestroni G., Alessio E., Sava G., Pacor S., Coluccia M., Boccarelli A. Water-soluble ruthenium(III)-dimethyl sulfoxide complexes: chemical behaviour and pharmaceutical properties Met. Based Drugs 1994 1, N 1 P. 41–63.
[7] Alessio E., Mestroni G., Bergamo A., Sava G. Ruthenium antimetastatic agents Curr. Top. Med. Chem 2004 4, N 15 P. 1525–1535.
[8] Lipponer K. G., Vogel E., Keppler B. K. Synthesis, characterization and solution chemistry of trans-indazoliumtetrachlorobis(indazole) ruthenate(III), a new anticancer ruthenium complex. IR, UV, NMR, HPLC investigations and antitumor activity. Crystal structures of trans-l-methyl-indazoliumtetrachlorobis-(1-methylindazole)ruthenate(III) and its hydrolysis product trans-monoaquatrichlorobis-(1-methylindazole)ruthenate(III) Met. Based Drugs 1996 3, N 5 P. 243–260.
[9] Hartinger C. G., Zorbas-Seifried S., Jakupec M. A., Kynast B., Zorbas H., Keppler B. K. From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) J. Inorg. Biochem 2006 100, N 5–6 P. 891–904.
[10] Vilaplana-Serrano R., Basallote M. G., Ruiz-Valero C., Gutierrez-Puebla E., Gonzalez-Vilchez F. Synthesis and X-ray structural study of a novel ruthenium (III)–ethylenediaminetetraacetate complex. The first compound showing an unusual coordination site for a carboxylic (glycine) group J. Chem. Soc. Chem. Commun 1991 N 2 P. 100–101.
[11] Frasca D. R., Gehrig L. E., Clarke M. J. Cellular effects of transferrin coordinated to [Cl(NH3)5Ru]Cl2 and cis-[Cl2(NH3)4Ru]Cl J. Inorg. Biochem 2001 83, N 2– 3 P. 139–149.
[12] Messori L., Kratz F., Alessio E. The interaction of the antitumor complexes Na[trans-RuCl4(DMSO)(Im)] and Na[transRuCl4(DMSO)(Ind)] with apotransferrin: a spectroscopic study Met. Based Drugs 1996 3, N 1 P. 1–9.
[13] Bergamo A., Messori L., Piccioli F., Cocchietto M., Sava G. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferring Invest. New Drugs 2003 21, N 4 P. 401–411.
[14] Kratz F., Keppler B. K., Messori L., Smith C., Baker E. N. Protein-binding properties of two antitumour Ru(III) complexes to human apotransferrin and apolactoferrin Met. Based Drugs 1994 1, N 2–3 P. 169–173.
[15] Piccioli F., Sabatini S., Messori L., Orioli P., Hartinger Ch. G., Keppler B. K. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4 (Ind)2] and serum proteins J. Inorg. Biochem 2004 98, N 6 P. 1135–1142.
[16] Gonzalez V. F., Vilaplana R., Blasco G., Messori L. Solution studies of the antitumor complex dichloro 1,2-propylendiaminetetraacetate ruthenium (III) and of its interactions with proteins J. Inorg. Biochem 1998 71, N 1–2 P. 45–51.
[17] Badea M., Olar R., Marinescu D., Uivarosi V., Iacob D. Thermal decomposition of some biologically active complexes of ruthenium (III) with quinolone derivatives J. Therm. Anal. Calorim 2009 97, N 2 P. 735–739.
[18] Badea M., Olar R., Marinescu D., Uivarosi V., Nicolescu T. O., Iacob D. Thermal study of some new quinolone ruthenium(III) complexes with potential cytostatic activity J. Therm. Anal. Calorim 2010 99, N 3 P. 829–834.
[19] Rau G., Mogosanu G.-D., Stanciulescu C. E. Synthesis and characterization of some novel azoderivatives Farmacia 2009 57, N 5 P. 648–658.
[20] Jurca T., Marian E. Scanning electronic microscopy study of new pyrazinamide compounds with metallic ions Farmacia 2009 57, N 2 P. 247–253.